Trazimera (trastuzumab)

pCPA File Number: 21728
Negotiation Status:
Concluded with an LOI
Indication(s):
Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Sponsor/Manufacturer:
Pfizer Canada ULC
CDA-AMC Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded: